Linked Life Data

16176400

Source:http://linkedlifedata.com/resource/pubmed/id/16176400

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-9-22
pubmed:abstractText
Parallel follow-up of clinical and inflammatory markers during sub-lingual immunotherapy (SLIT) is highly beneficial. Twenty-four children (age 4-16) monosensitized to house dust mite were randomized to receive either active or placebo SLIT for 1 yr in a double-blind placebo controlled design (Marcucci et al., Allergy 2003: 58: 657-62). Thereafter, for 2 yr they all received active treatment. Symptom scores for rhinitis, asthma, and drug usage were daily recorded. Eosinophil cationic protein (ECP) and tryptase in sputum and nasal secretions, serum and nasal mite-specific immunoglobulin E (IgE) were recorded before treatment and at 10-12 months intervals. Nasal ECP and nasal tryptase after specific nasal provocation tests were significantly reduced as compared to baseline values (p = 0.0043 and 0.0195, respectively) in the third year of active treatment. None of the other inflammatory parameters was increased. In placebo treated patients all these parameters tended to decrease only after switching to active treatment. Clinical scores did not improve in treated vs. placebo patients in the double-blind placebo-controlled phase of the study. In both cohorts a clinical benefit was observed as intra-group score reduction as compared to baseline. A significant difference was reached in patients treated for 2 yr for rhinitis and asthma (p = 0.0009 and 0.0019, respectively) but not for drug usage and in patients treated for 3 yr for rhinitis, asthma, and drug usage (p = 0.0105, 0.0048, and 0.02, respectively). SLIT in children monosensitized to mites reverted the spontaneous increase in nasal IgE and in local parameters of allergic inflammation. These outcomes were followed by a consolidated clinical improvement in the second and third year of treatment.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0905-6157
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
519-26
pubmed:dateRevised
2008-5-28
pubmed:meshHeading
pubmed-meshheading:16176400-Administration, Sublingual, pubmed-meshheading:16176400-Adolescent, pubmed-meshheading:16176400-Animals, pubmed-meshheading:16176400-Anti-Asthmatic Agents, pubmed-meshheading:16176400-Antibody Specificity, pubmed-meshheading:16176400-Asthma, pubmed-meshheading:16176400-Child, pubmed-meshheading:16176400-Child, Preschool, pubmed-meshheading:16176400-Child Welfare, pubmed-meshheading:16176400-Desensitization, Immunologic, pubmed-meshheading:16176400-Double-Blind Method, pubmed-meshheading:16176400-Eosinophil Cationic Protein, pubmed-meshheading:16176400-Follow-Up Studies, pubmed-meshheading:16176400-Histamine H1 Antagonists, pubmed-meshheading:16176400-Humans, pubmed-meshheading:16176400-Immunization, pubmed-meshheading:16176400-Immunoglobulin E, pubmed-meshheading:16176400-Inflammation Mediators, pubmed-meshheading:16176400-Pyroglyphidae, pubmed-meshheading:16176400-Rhinitis, Allergic, Perennial, pubmed-meshheading:16176400-Serine Endopeptidases, pubmed-meshheading:16176400-Tryptases
pubmed:year
2005
pubmed:articleTitle
Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy.
pubmed:affiliation
Clinica Pediatrica, University of Perugia, Italy.
pubmed:publicationType
Journal Article, Randomized Controlled Trial